Klasson; Bjorn

Patent Applications and Registrations

Patent applications and USPTO patent grants for Klasson; Bjorn.The latest application filed is for "base-modified cytidine nucleotides for leukemia therapy".

Company Profile

7.13.16

Klasson; Bjorn - Huddinge SE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Dioxolane analogues of uridine for the treatment of cancer Grant 11,447,511 - Bethell , et al. September 20, 2	2022-09-20
Base-Modified Cytidine Nucleotides for Leukemia Therapy App 20210261584 - PINHO; Pedro ; et al.	2021-08-26
Sorafenib or regorafenib troxacitabine phosphoramidate prodrug combination therapy for liver cancer Grant 10,960,017 - Albertella , et al. March 30, 2	2021-03-30
Dioxolane Analogues Of Uridine For The Treatment Of Cancer App 20210054008 - BETHELL; Richard ; et al.	2021-02-25
Cancer Treatment With (2,2-bishydroxymethyl) Methylenecyclopropane Nucleotides App 20200399295 - KLASSON; Bjorn ; et al.	2020-12-24
Dioxolane analogues of uridine for the treatment of cancer Grant 10,822,360 - Bethell , et al. November 3, 2	2020-11-03
Dioxolane Analogues Of Uridine For The Treatment Of Cancer App 20200239502 - BETHELL; Richard ; et al.	2020-07-30
Dioxolane analogues of uridine for the treatment of cancer Grant 10,654,877 - Bethell , et al.	2020-05-19
Sorafenib Or Regorafenib Troxacitabine Phosphoramidate Prodrug Combination Therapy For Liver Cancer App 20200009166 - Albertella; Mark ; et al.	2020-01-09
Dioxolane Analogues Of Uridine For The Treatment Of Cancer App 20190389890 - BETHELL; Richard ; et al.	2019-12-26
Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine Grant 10,456,413 - Albertella , et al. Oc	2019-10-29
Dioxolane analogues of uridine for the treatment of cancer Grant 10,336,780 - Bethell , et al.	2019-07-02
Dioxolane Analogues Of Uridine For The Treatment Of Cancer App 20190100541 - BETHELL; Richard ; et al.	2019-04-04
Combination Therapy With Sorafenib Or Regorafenib And A Phosphoramidate Prodrug Of Troxacitabine App 20190091246 - ALBERTELLA; Mark ; et al.	2019-03-28
Dioxolane analogues of cytidine for the treatment of cancer Grant 10,144,750 - Bethell , et al. De	2018-12-04
Dioxolane Analogues Of Uridine For The Treatment Of Cancer App 20170267705 - BETHEL; Richard ; et al.	2017-09-21
Cysteine Protease Inhibitors App 20150025250 - AYESA; Susana ; et al.	2015-01-22
Cysteine protease inhibitors Grant 8,859,505 - Ayesa , et al. October 14, 2	2014-10-14
Cysteine protease inhibitors Grant 8,859,605 - Ayesa , et al. October 14, 2	2014-10-14
Cysteine protease inhibitors Grant 8,815,809 - Ayesa , et al. August 26, 2	2014-08-26
Hcv Polymerase Inhibitors App 20140066398 - ENEROTH; Anders ; et al.	2014-03-06
Cysteine Protease Inhibitors App 20130172232 - Ayesa; Susana ; et al.	2013-07-04
HCV Polymerase Inhibitors App 20130143835 - ENEROTH; Anders ; et al.	2013-06-06
Cysteine Protease Inhibitors App 20120309673 - Ayesa; Susana ; et al.	2012-12-06
Cysteine Protease Inhibitors App 20120283305 - Ayesa; Susana ; et al.	2012-11-08

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.